News In Brief

Avara buys AZ solid dose facility in France

By Flora Southey

- Last updated on GMT


Related tags Pharmacology

Avara Pharmaceutical Services will buy AstraZeneca’s secondary solid dosage form manufacturing, packaging and distribution facility in Reims, France.

Avara CEO Timothy Tyson said the acquisition will expand the contract development and manufacturing organisation’s (CDMO) offering.

“This key acquisition is another important component of our strategic plan that further expands our services,” ​said Tyson.

Secondary manufacturing services include granulation, blending, coating, encapsulation, compression and drying of tablets and capsules. 

AstraZeneca told us 130 of its employees will be transferred to Avara. 

Buying power

This is the third manufacturing facility Avara has purchased from a large-scale pharmaceutical firm in just over a year.

In September 2016, the company announced​ it would buy AstraZeneca’s Avlon, England-based active pharmaceutical ingredient (API) plant.

In August of this year, Avara agreed​ to purchase a sterile drug manufacturing facility from Pfizer in Liscate, Italy.

Avara now has sites in France, the US, the UK, Ireland, Italy and Puerto Rico. 

Related topics Contract Manufacturing & Logistics

Related news

Show more